- Previous Close
1.0600 - Open
1.0600 - Bid 1.0000 x 500
- Ask 1.0300 x 400
- Day's Range
0.9348 - 1.0600 - 52 Week Range
0.9348 - 5.6400 - Volume
7,530,474 - Avg. Volume
478,654 - Market Cap (intraday)
88.544M - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-2.4600 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.90
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
www.allakos.comRecent News: ALLK
View MorePerformance Overview: ALLK
Trailing total returns as of 6/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALLK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALLK
View MoreValuation Measures
Market Cap
93.86M
Enterprise Value
-4.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.90
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.60%
Return on Equity (ttm)
-111.56%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-214.44M
Diluted EPS (ttm)
-2.4600
Balance Sheet and Cash Flow
Total Cash (mrq)
139.25M
Total Debt/Equity (mrq)
38.88%
Levered Free Cash Flow (ttm)
-52.64M